Search Clinical Trials

REFINE SEARCH
20 Results   |   Clear Filters

Age group

Category

Primary purpose

Study type

Location

Principal investigator

Search results

Displaying 1 - 20 of 20

Open Actively Recruiting

COVID-19 Outcome Prediction Algorithm

严重急性呼吸综合征冠状病毒2介导的冠状病毒病(COVID-19)是一种进化上前所未有的自然实验,会导致宿主免疫系统发生重大变化. 我们建议开发一种测试,通过临床和分子数据准确预测住院COVID-19患者的短期和长期(一年内)结果,广泛反映美国人口统计数据,这些人口统计数据增加了COVID-19不良后果的风险. 我们将从全国最大的城市之一的住院平民人口和具有代表性的国家退伍军人人口中招募患者.

Gender: All
Age Group: Adults
Contact: GALYNA BONDAR
Investigator: Mario C. Deng, MD
Open Actively Recruiting

奥贝德西韦治疗儿童和青少年COVID-19的研究

本临床研究的目的是进一步了解奥贝德西韦(obeldesivir, ODV)治疗2019冠状病毒病(COVID-19)儿童和青少年的安全性和耐受性。.

主要目的是评估血浆药代动力学(PK)。, ODV在小儿COVID-19患者中的安全性和耐受性.

Phase: Phase 2/Phase 3
Primary Purpose: Treatment
Gender: All
Age Group: Children
Contact: Michele Carter
Open Actively Recruiting

The Effect of the COVID-19 Pandemic on Glaucoma Care

This study has not yet been registered on ClinicalTrials.Gov,这是目前显示详细资格标准的先决条件.

Age Group: Adults, Children
Contact: Margarita Gonzalez
Investigator: Simon K. Law, MD
Open Actively Recruiting

Understanding COVID-19 in Patients with Rheumatic Disease

This study has not yet been registered on ClinicalTrials.Gov,这是目前显示详细资格标准的先决条件.

Age Group: Adults
Contact: Tiffany De Leon
Open Actively Recruiting

皇冠hga025大学洛杉矶分校类风湿性关节炎患者COVID-19问卷调查

This study has not yet been registered on ClinicalTrials.Gov,这是目前显示详细资格标准的先决条件.

Age Group: Adults
Contact: Michelle Ramirez
Open Actively Recruiting

皇冠hga025大学洛杉矶分校新冠肺炎住院患者观察队列研究

This study has not yet been registered on ClinicalTrials.Gov,这是目前显示详细资格标准的先决条件.

Age Group: Adults, Children
Contact: Adreanne Rivera
Open Actively Recruiting

托珠单抗在小儿COVID-19住院患者中的应用研究

This is a single-arm, open-label study to assess the pharmacokinetics, pharmacodynamics, safety, tocilizumab (TCZ)治疗出生至18岁以下住院的COVID-19患儿,接受全身性皮质类固醇治疗,需要补充氧气或机械通气.

Phase: Phase 1
Primary Purpose: Treatment
Gender: All
Age Group: Children
Contact: Sai Sravya Sankar
Open Actively Recruiting

一项评估受COVID-19影响的母婴对病毒脱落和免疫反应发展的观察性研究

这项研究的目的是了解孕妇及其新生儿在怀孕期间对SARS-CoV-2感染的反应, the virus responsible for COVID-19. 该研究的两个主要目的是:1)随着时间的推移,评估被诊断为COVID-19的孕妇及其新生儿中病毒的存在和抗体的发展, 2)监测相同血液样本中疾病严重程度的标志物. The research study will last one year. 在入组时,我们将采集您的血液样本,检查是否存在抗体和疾病严重程度的标志物, at delivery, 6-weeks, 6-months and 12-months. 我们将在你的宝宝出生后24小时(在医院)采集血液样本, with routine labs), at 6 months, and 12 months. 我们还会在分娩时收集您的鼻咽拭子,以检测您的鼻子中是否存在病毒, and from your baby within 48 hours of life. 我们希望您和您的宝宝参加本次研究共4次访问, 每次评估持续约30分钟,直到出生后1年.

Age Group: Adults, Children
Contact: Tara Kerin
Open Actively Recruiting

Strategies and Treatments for Respiratory Infections & 病毒紧急情况(STRIVE):免疫调节策略试验

COVID-19 can trigger a dysregulated immune response, 先前的研究表明,免疫调节可以改善住院患者的预后. 该试验旨在确定与安慰剂+ SOC(安慰剂组)相比,在病程早期(患者接受低流量供氧时)加强阿巴接受(活性组)联合标准护理(SOC)是否能改善康复。. For both groups, 如果出现疾病进展迹象(患者需要高流量鼻氧(HFNO)或更多支持)和/或患者需氧量迅速增加,将作为SOC的一部分提供强化免疫调节.

Phase: Phase 4
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Lorenzo Duvergne
Investigator: George W. Lim, MD
Open Actively Recruiting

Strategies and Treatments for Respiratory Infections & 紧急病毒(STRIVE):盐野义蛋白酶抑制剂(Ensitrelvir)

需要治疗来改善COVID-19住院患者的预后, 包括直接作用抗病毒药物(DAA),以减轻由正在进行的病毒复制驱动的病理. This trial will evaluate S-217622 (ensitrelvir), Shionogi开发的抗sars - cov2 3c样蛋白酶抑制剂(PI &; Co. Ltd.

The study design is a randomized, placebo-controlled, 多中心国际临床试验,将评估在标准护理(SOC)之外给予ensitrelvir治疗COVID-19住院患者的临床疗效. SOC将由当地制定的指南确定,并可能包括额外的DAA(例如.g., remdesivir) and immunomodulatory treatment strategies. 在随机化之前,将预先指定某些SOC治疗.

Phase: Phase 3
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Julia Vargas
Investigator: George W. Lim, MD
Open Actively Recruiting

EPIC-Peds:一项关于研究药物PF-07321332 (Nirmatrelvir)/Ritonavir用于18岁以下未住院但有严重疾病风险的COVID-19患者的研究

本临床试验的目的是了解其安全性, 药代动力学(药代动力学帮助我们了解服药后药物是如何变化和从体内排出的), 研究药物(称为nirmatrelvir/ritonavir)用于潜在治疗2019冠状病毒病(COVID-19)的疗效(研究治疗在研究中的效果).

该研究药物将用于18岁以下未住院但有严重疾病风险的COVID-19患者.

Phase: Phase 2/Phase 3
Primary Purpose: Treatment
Gender: All
Age Group: Children
Contact: Yun Yong Lei
Open Actively Recruiting

COVID-19在医护人员和患者中的监测:来自重症(IVY)网络流感疫苗有效性的观察性研究

This study has not yet been registered on ClinicalTrials.Gov,这是目前显示详细资格标准的先决条件.

Age Group: Adults
Contact: Nida Qadir
Investigator: Nida Qadir, MD
Open Actively Recruiting

2019新型冠状病毒急性呼吸系统疾病体外膜氧合重症监护联盟(ECMOCARD)

This study has not yet been registered on ClinicalTrials.Gov,这是目前显示详细资格标准的先决条件.

Age Group: Adults, Children
Contact: Jennifer Scovotti
Open Actively Recruiting

COVID应急皇冠hga025(COVERED)项目风险评估

这项由美国疾病控制与预防中心赞助的监测项目旨在评估急诊皇冠hga025工作人员的风险暴露和COVID-19感染情况. 该项目将要求参与者提供有关风险暴露的持续信息, 并将收集有关机构和皇冠hga020电脑版风险的额外信息. 这些风险评估将与疾病状况评估结合起来, as determined by serologic testing at two-week intervals. 该项目的目标是确定急诊科人员在处理冠状病毒大流行时面临的最重要和潜在可纠正的风险因素.

Age Group: Adults
Contact: Julia Vargas
Open Actively Recruiting

错配肾移植患者的免疫耐受

本研究旨在确定在接受人类白细胞抗原(HLA)单倍型匹配相关或0-3抗原联合治疗的受试者中,使用药物白莫硫地尔(KD025)是否安全并能改善移植耐受性, B, C, HLA错配无亲缘关系活体供体肾和造血干细胞移植.

Phase: Phase 1
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: DANA LEVIN-LOPEZ
Investigator:
NEIL KOGUT
Open Actively Recruiting

机械干预治疗COVID-19 VV ECMO患者持续性低氧血症:一项多中心回顾性研究

This study has not yet been registered on ClinicalTrials.Gov,这是目前显示详细资格标准的先决条件.

Age Group: Adults
Contact: Jennifer Scovotti
Open Actively Recruiting

SARS-CoV-2感染急性后遗症(PASC)后自主神经异常的正念

目前的试点研究将招募有新经历的参与者, returning, 或在首次感染SARS-CoV-2后至少四周内出现与COVID-19疾病相关的持续症状. 所有参与者都将参加一个名为“正念意识练习”(MAPs)的虚拟课程,为期6周, 由皇冠hga025大学洛杉矶分校正念意识研究中心(MARC)的专家主持和领导,. This intervention will consist of a mix of lecture, practice, group feedback, and discussion regarding mindfulness. 正念是一种精神状态,通过将一个人的意识集中在现在,同时承认和接受任何感觉, thoughts, or bodily sensations. 研究小组将收集心理健康症状的自我报告, physical health symptoms, 以及参与者参加MAPs前后的人口统计信息. 研究小组还将收集客观的健康措施,包括主动站立测试, a 6-minute walk, and a blood sample.

Phase: N/A
Primary Purpose: Supportive care
Gender: Female
Age Group: Adults
Contact: ELIZABETH VANDENBOGAART
Open Actively Recruiting

Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder

本研究将评估GWP42003-P的疗效, compared with placebo, 减轻自闭症谱系障碍(ASD)儿童症状严重程度的作用.

Phase: Phase 2
Primary Purpose: Treatment
Gender: All
Age Group: Children
Contact: JENNIFER COWEN
Investigator:
James McCracken
Open Actively Recruiting

单剂重组呼吸道合胞病毒(RSV)减毒活疫苗RSV ΔNS2/Δ1313/I1314L的安全性和免疫原性, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, 给6 - 24月龄rsv血清阴性儿童滴鼻剂

本研究的目的是评价单剂量重组呼吸道合胞病毒减毒活疫苗的安全性和免疫原性, RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, and RSV 276, in RSV-seronegative children 6 to 24 months of age.

Phase: Phase 1/Phase 2
Primary Purpose: Prevention
Gender: All
Age Group: Children
Contact: Michele Carter
Open Actively Recruiting

评估口服ABBV-525片的b细胞恶性肿瘤成年患者的不良事件和疾病活动性变化的研究

B-cell malignancies are a group of cancers of B lymphocytes, 一种白细胞,负责抵抗感染. The purpose of this study is to assess safety, tolerability, ABBV-525单药的药代动力学和初步疗效.

ABBV-525是一种用于治疗b细胞恶性肿瘤的研究药物. 研究医生将参与者分成治疗组. Participants will receive ABBV-525 at different doses. 大约100名成年参与者将在全球各地参加这项研究.

在第1部分(剂量递增)中,参与者将接受逐步递增的口服ABBV-525剂量. In part 2 (dose optimization), participants will receive one of two oral doses of ABBV-525, until the recommended phase 2 dose (RP2D) is determined. 在第3部分(剂量扩展)中,参与者将接受RP2D口服剂量ABBV-525. The estimated duration of the study is up to 64 months.

与他们的护理标准相比,本试验参与者的治疗负担可能更高. 在研究期间,参与者将定期到医院或诊所就诊,并可能需要经常进行医疗评估, blood tests, and scans.

Phase: Phase 1
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Efrata Negatu